SAN DIEGO

CA

92130

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	ection	1 30(h) of the	Ínvestr	nent C	ompany Act o	f 1940								
Name and Address of Reporting Person* MVA Investors, LLC				2. Issuer Name and Ticker or Trading Symbol Tango Therapeutics, Inc. [TNGX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director							
(Last) (First) (Middle) 12860 EL CAMINO REAL				3. Date of Earliest Transaction (Month/Day/Year) 05/01/2024							Officer (give title X Other (specify below) See remarks								
l —				4. If	Amen	ndment, Dat	of Orig	inal Fil	ed (Month/Da	ıy/Year)		6. Individual or Joint/Group Filing (Check Applicable							
(Street)	treet)											Line) Form filed by One Reporting Person Form filed by More than One Reporting Person							
SAN DII	EGO	CA	92130																
(City)		(State)	(Zip)		$ _{\Box}$	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									ntended to				
		Tab	le I - N	on-Deriva	tive	Seci	urities A	quire	d, Di	sposed of	, or B	enefic	cial	ly Own	ed				
1. Title of Security (Instr. 3) 2. Transa Date		2. Transact Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		Code	action (Instr.	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 s 5)		4 and Securition Benefici Owned I		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Common Stock		05/01/2	024			S		75,000	D	\$7.4	.43(1) 618		618,524		Ι	See footnote ⁽²⁾		
Common Stock			05/02/2	2024					75,000	D	\$7.5	7.56 ⁽³⁾ 543		543,524		I	See footnote ⁽²⁾		
Common Stock		05/03/2	2024					60,000	D	\$7.6	57.61 ⁽⁴⁾ 483		483,524		I	See footnote ⁽²⁾			
Common Stock												5,000		Ι	See footnote ⁽⁵⁾				
		-	Table II							oosed of, convertib				Owne	d				
1. Title of	2.	3. Transaction	3A. D	eemed	4.	ans,	5. Numbe	-	-		7. Title		÷	Price of	9. Numbe	r of	10.	11. Nature	
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	on Date (Month/Day/Yea	Execu ar) if any	ution Date,	Trans Code 8)		n of	Expire (Mon	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative Security (Inst		D S (I	erivative ecurity nstr. 5)	derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s lly	Ownersh Form: Direct (D or Indirec (I) (Instr.	ip of Indirect Beneficial Ownership t (Instr. 4)	
							ΤÍ					Amoun	t						
					Code	v	(A) (D	Date Exer	cisable	Expiration Date		or Numbe of Shares							
1. Name ar		of Reporting Persons, <u>LLC</u>	on [*]																
(Last)		(First)	(N	fiddle)															
12860 E	L CAMII	NO REAL																	
SUITE 3	00																		
(Street)						-													
SAN DII	EGO	CA	92	2130															
(City)		(State)	(Z	lip)		_													
1. Name at Davis		of Reporting Person	on [*]																
(Last) 12860 E	L CAMII	(First) NO REAL, SUI	,	Middle)															
						- 1													

(State)	(Zip)	
	(State)	(State) (Zip)

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.39 to \$7.79, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 2. These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.50 to \$7.59, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$7.56 to \$7.81, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- 5. These securities are owned directly by Mr. Davis. Each reporting person other than Mr. Davis disclaims beneficial ownership of these securities.

Remarks:

The reporting persons may be deemed members of a group that beneficially owns more than 10% of the outstanding shares of common stock, \$0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. As to any reporting person that is not a beneficial owner of more than 10% of the outstanding shares of Common Stock, this Form 4 shall not be deemed a concession that such person is subject to Section 16 of the Securities Exchange Act of 1934 with respect to the issuer.

/s/ Aaron I. Davis, Chief Executive Officer, MVA 05/03/2024 Investors, LLC

<u>/s/ Aaron I. Davis</u> <u>05/03/2024</u>

Date

** Signature of Reporting Person Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.